

Manige Konig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9640169/publications.pdf>

Version: 2024-02-01

9
papers

106
citations

1477746
6
h-index

1473754
9
g-index

9
all docs

9
docs citations

9
times ranked

108
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. Cardiovascular Diabetology, 2021, 20, 194.	2.7	29
2	Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide <scp>Bcise</scp>: 6â€month followâ€up from <scp>US realâ€world</scp> data. Diabetes, Obesity and Metabolism, 2021, 23, 106-115.	2.2	20
3	Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review. Diabetes Therapy, 2020, 11, 1437-1466.	1.2	15
4	Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1345-1351.	1.8	14
5	Cardiovascular outcomes trials with glucagonâ€like peptideâ€1 receptor agonists: A comparison of study designs, populations and results. Diabetes, Obesity and Metabolism, 2020, 22, 2209-2226.	2.2	11
6	Efficacy and safety of dulaglutide 3.0â€and 4.5â€mg in patients agedâ€younger thanâ€65 andâ€65â€years or older: Post hoc analysis of the <scp>AWARD</scp>â€1 trial. Diabetes, Obesity and Metabolism, 2021, 23, 2279-2288.	2.2	6
7	A modelâ€based simulation of glycemic control and body weight when switching from semaglutide to 3.0 and 4.5 mg doses of onceâ€weekly dulaglutide. Diabetes, Obesity and Metabolism, 2021, 24, 302.	2.2	6
8	HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial. Diabetes Care, 2022, , .	4.3	4
9	Examining the evidence for weight management in individuals with type 2 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 1411-1422.	2.2	1